Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Relationship between morphological features and kinetic patterns of enhancement of the dynamic breast magnetic resonance imaging and clinico-pathological and biological factors in invasive breast cancer

Authors: Oscar Fernández-Guinea, Alejandro Andicoechea, Luis O González, Salomé González-Reyes, Antonio M Merino, Luis C Hernández, Alfonso López-Muñiz, Paz García-Pravia, Francisco J Vizoso

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

To investigate the relationship between the magnetic resonance imaging (MRI) features of breast cancer and its clinicopathological and biological factors.

Methods

Dynamic MRI parameters of 68 invasive breast carcinomas were investigated. We also analyzed microvessel density (MVD), estrogen and progesterone receptor status, and expression of p53, HER2, ki67, VEGFR-1 and 2.

Results

Homogeneous enhancement was significantly associated with smaller tumor size (T1: < 2 cm) (p = 0.015). Tumors with irregular or spiculated margins had a significantly higher MVD than tumors with smooth margins (p = 0.038). Tumors showing a maximum enhancement peak at two minutes, or longer, after injecting the contrast, had a significantly higher MVD count than those which reached this point sooner (p = 0.012). The percentage of tumors with vascular invasion or high mitotic index was significantly higher among those showing a low percentage (≤ 150%) of maximum enhancement before two minutes than among those ones showing a high percentage (>150%) of enhancement rate (p = 0.016 and p = 0.03, respectively). However, there was a significant and positive association between the mitotic index and the peak of maximum intensity (p = 0.036). Peritumor inflammation was significantly associated with washout curve type III (p = 0.042).

Conclusions

Variations in the early phase of dynamic MRI seem to be associated with parameters indicatives of tumor aggressiveness in breast cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Orel SG, Schnall MD, Powell CM, Hochman MG, Solin LJ, Fowble BL, Torosian MH, Rosato EF: Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology. 1995, 196: 115-122.CrossRefPubMed Orel SG, Schnall MD, Powell CM, Hochman MG, Solin LJ, Fowble BL, Torosian MH, Rosato EF: Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology. 1995, 196: 115-122.CrossRefPubMed
2.
go back to reference Liberman L: Breast MR imaging in assessing extent of disease. Magn Reson Imaging Clin N Am. 2006, 14: 339-349. 10.1016/j.mric.2006.07.007.CrossRefPubMed Liberman L: Breast MR imaging in assessing extent of disease. Magn Reson Imaging Clin N Am. 2006, 14: 339-349. 10.1016/j.mric.2006.07.007.CrossRefPubMed
3.
go back to reference Kuhl C: Current status of breast MR imaging. Part 2. Clinical applications. Radiology. 2007, 244: 672-691. 10.1148/radiol.2443051661.CrossRefPubMed Kuhl C: Current status of breast MR imaging. Part 2. Clinical applications. Radiology. 2007, 244: 672-691. 10.1148/radiol.2443051661.CrossRefPubMed
4.
go back to reference Boetes C, Barentsz JO, Mus RD, Sluis van der RF, van Erning LJ, Hendriks JH, Holland R, Ruys SH: MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology. 1994, 193: 777-781.CrossRefPubMed Boetes C, Barentsz JO, Mus RD, Sluis van der RF, van Erning LJ, Hendriks JH, Holland R, Ruys SH: MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology. 1994, 193: 777-781.CrossRefPubMed
5.
go back to reference Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, Schild HH: Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?. Radiology. 1999, 211: 101-110.CrossRefPubMed Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, Schild HH: Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?. Radiology. 1999, 211: 101-110.CrossRefPubMed
6.
go back to reference Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, Leach MO, Husband JE: Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology. 2006, 239: 361-374. 10.1148/radiol.2392021099.CrossRefPubMed Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, Leach MO, Husband JE: Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology. 2006, 239: 361-374. 10.1148/radiol.2392021099.CrossRefPubMed
7.
go back to reference Hylton N: MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am. 2006, 14: 383-389. 10.1016/j.mric.2006.09.001.CrossRefPubMed Hylton N: MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am. 2006, 14: 383-389. 10.1016/j.mric.2006.09.001.CrossRefPubMed
8.
go back to reference Bone B, Szabo BK, Perbeck LG, Veress B, Aspelin P: Can contrast-enhanced MR imaging predict survival in breast cancer?. Acta Radiol. 2003, 44: 373-378.CrossRefPubMed Bone B, Szabo BK, Perbeck LG, Veress B, Aspelin P: Can contrast-enhanced MR imaging predict survival in breast cancer?. Acta Radiol. 2003, 44: 373-378.CrossRefPubMed
9.
go back to reference Matsubayashi R, Matsuo Y, Edakuni G, Satoh T, Tokunaga O, Kudo S: Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology. 2000, 217: 841-848.CrossRefPubMed Matsubayashi R, Matsuo Y, Edakuni G, Satoh T, Tokunaga O, Kudo S: Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology. 2000, 217: 841-848.CrossRefPubMed
10.
go back to reference Tuncbilek N, Karakas HM, Okten OO: Dynamic magnetic resonance imaging in determining histopathological prognostic factors of invasive breast cancers. Eur J Radiol. 2005, 53: 199-205. 10.1016/j.ejrad.2003.11.004.CrossRefPubMed Tuncbilek N, Karakas HM, Okten OO: Dynamic magnetic resonance imaging in determining histopathological prognostic factors of invasive breast cancers. Eur J Radiol. 2005, 53: 199-205. 10.1016/j.ejrad.2003.11.004.CrossRefPubMed
11.
go back to reference Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE: Androgen receptor and invasion in prostate cancer. Cancer Res. 2008, 68: 1128-1135. 10.1158/0008-5472.CAN-07-1929.CrossRefPubMed Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE: Androgen receptor and invasion in prostate cancer. Cancer Res. 2008, 68: 1128-1135. 10.1158/0008-5472.CAN-07-1929.CrossRefPubMed
12.
go back to reference Montemurro F, Martincich L, Sarotto I, Bertotto I, Ponzone R, Cellini L, Redana S, Sismondi P, Aglietta M, Regge D: Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. Eur Radiol. 2007, 17: 1490-1497. 10.1007/s00330-006-0505-x.CrossRefPubMed Montemurro F, Martincich L, Sarotto I, Bertotto I, Ponzone R, Cellini L, Redana S, Sismondi P, Aglietta M, Regge D: Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. Eur Radiol. 2007, 17: 1490-1497. 10.1007/s00330-006-0505-x.CrossRefPubMed
13.
go back to reference Dixon AR, Ellis IO, Elston CW, Blamey RW: A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. Br J Cancer. 1991, 63: 634-635.CrossRefPubMedPubMedCentral Dixon AR, Ellis IO, Elston CW, Blamey RW: A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. Br J Cancer. 1991, 63: 634-635.CrossRefPubMedPubMedCentral
14.
go back to reference Liu N, Lapcevich RK, Underhill CB, Han Z, Gao F, Swartz G, Plum SM, Zhang L, Green SJ: Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res. 2001, 61: 1022-1028.PubMed Liu N, Lapcevich RK, Underhill CB, Han Z, Gao F, Swartz G, Plum SM, Zhang L, Green SJ: Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res. 2001, 61: 1022-1028.PubMed
15.
go back to reference Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998, 11: 155-168.PubMed Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998, 11: 155-168.PubMed
16.
go back to reference BI-RADS: American College of Radiology. Breast imaging reporting and data system. 2003, Reston, VA: American College of Radiology, 4 BI-RADS: American College of Radiology. Breast imaging reporting and data system. 2003, Reston, VA: American College of Radiology, 4
17.
go back to reference Stomper PC, Herman S, Klippenstein DL, Winston JS, Edge SB, Arredondo MA, Mazurchuk RV, Blumenson LE: Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology. 1995, 197: 387-395.CrossRefPubMed Stomper PC, Herman S, Klippenstein DL, Winston JS, Edge SB, Arredondo MA, Mazurchuk RV, Blumenson LE: Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology. 1995, 197: 387-395.CrossRefPubMed
18.
go back to reference Fischer U, Kopka L, Brinck U, Korabiowska M, Schauer A, Grabbe E: Prognostic value of contrast-enhanced MR mammography in patients with breast cancer. Eur Radiol. 1997, 7: 1002-1005. 10.1007/s003300050240.CrossRefPubMed Fischer U, Kopka L, Brinck U, Korabiowska M, Schauer A, Grabbe E: Prognostic value of contrast-enhanced MR mammography in patients with breast cancer. Eur Radiol. 1997, 7: 1002-1005. 10.1007/s003300050240.CrossRefPubMed
19.
go back to reference Lee SH, Cho N, Kim SJ, Cha JH, Cho KS, Ko ES, Moon WK: Correlation between high resolution dynamic MR features and prognostic factors in breast cancer. Korean J Radiol. 2008, 9: 10-18. 10.3348/kjr.2008.9.1.10.CrossRefPubMedPubMedCentral Lee SH, Cho N, Kim SJ, Cha JH, Cho KS, Ko ES, Moon WK: Correlation between high resolution dynamic MR features and prognostic factors in breast cancer. Korean J Radiol. 2008, 9: 10-18. 10.3348/kjr.2008.9.1.10.CrossRefPubMedPubMedCentral
20.
go back to reference Gilchrist KW, Kalish L, Gould VE, Hirschl S, Imbriglia JE, Levy WM, Patchefsky AS, Penner DW, Pickren J, Roth JA, et al: Interobserver reproducibility of histopathological features in stage II breast cancer. An ECOG study. Breast Cancer Res Treat. 1985, 5: 3-10. 10.1007/BF01807642.CrossRefPubMed Gilchrist KW, Kalish L, Gould VE, Hirschl S, Imbriglia JE, Levy WM, Patchefsky AS, Penner DW, Pickren J, Roth JA, et al: Interobserver reproducibility of histopathological features in stage II breast cancer. An ECOG study. Breast Cancer Res Treat. 1985, 5: 3-10. 10.1007/BF01807642.CrossRefPubMed
21.
go back to reference Elledge RM, McGuire WL, Osborne CK: Prognostic factors in breast cancer. Semin Oncol. 1992, 19: 244-253.PubMed Elledge RM, McGuire WL, Osborne CK: Prognostic factors in breast cancer. Semin Oncol. 1992, 19: 244-253.PubMed
22.
go back to reference Bone B, Aspelin P, Bronge L, Veress B: Contrast-enhanced MR imaging as a prognostic indicator of breast cancer. Acta Radiol. 1998, 39: 279-284.CrossRefPubMed Bone B, Aspelin P, Bronge L, Veress B: Contrast-enhanced MR imaging as a prognostic indicator of breast cancer. Acta Radiol. 1998, 39: 279-284.CrossRefPubMed
23.
go back to reference Frouge C, Guinebretiere JM, Contesso G, Di Paola R, Blery M: Correlation between contrast enhancement in dynamic magnetic resonance imaging of the breast and tumor angiogenesis. Invest Radiol. 1994, 29: 1043-1049. 10.1097/00004424-199412000-00006.CrossRefPubMed Frouge C, Guinebretiere JM, Contesso G, Di Paola R, Blery M: Correlation between contrast enhancement in dynamic magnetic resonance imaging of the breast and tumor angiogenesis. Invest Radiol. 1994, 29: 1043-1049. 10.1097/00004424-199412000-00006.CrossRefPubMed
24.
go back to reference Szabo BK, Aspelin P, Kristoffersen Wiberg M, Tot T, Bone B: Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol. 2003, 13: 2425-2435. 10.1007/s00330-003-2000-y.CrossRefPubMed Szabo BK, Aspelin P, Kristoffersen Wiberg M, Tot T, Bone B: Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol. 2003, 13: 2425-2435. 10.1007/s00330-003-2000-y.CrossRefPubMed
25.
go back to reference Teifke A, Behr O, Schmidt M, Victor A, Vomweg TW, Thelen M, Lehr HA: Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology. 2006, 239: 351-360. 10.1148/radiol.2392050205.CrossRefPubMed Teifke A, Behr O, Schmidt M, Victor A, Vomweg TW, Thelen M, Lehr HA: Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology. 2006, 239: 351-360. 10.1148/radiol.2392050205.CrossRefPubMed
26.
go back to reference Kuhl CK, Schild HH: Dynamic image interpretation of MRI of the breast. J Magn Reson Imaging. 2000, 12: 965-974. 10.1002/1522-2586(200012)12:6<965::AID-JMRI23>3.0.CO;2-1.CrossRefPubMed Kuhl CK, Schild HH: Dynamic image interpretation of MRI of the breast. J Magn Reson Imaging. 2000, 12: 965-974. 10.1002/1522-2586(200012)12:6<965::AID-JMRI23>3.0.CO;2-1.CrossRefPubMed
27.
go back to reference Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005, 69 (Suppl 3): 4-10. 10.1159/000088478.CrossRefPubMed Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005, 69 (Suppl 3): 4-10. 10.1159/000088478.CrossRefPubMed
28.
go back to reference Stomper PC, Herman S, Klippenstein DL, Winston JS, Budnick RM, Stewart CC: Invasive breast carcinoma: analysis of dynamic magnetic resonance imaging enhancement features and cell proliferative activity determined by DNA S-phase percentage. Cancer. 1996, 77: 1844-1849. 10.1002/(SICI)1097-0142(19960501)77:9<1844::AID-CNCR13>3.0.CO;2-#.CrossRefPubMed Stomper PC, Herman S, Klippenstein DL, Winston JS, Budnick RM, Stewart CC: Invasive breast carcinoma: analysis of dynamic magnetic resonance imaging enhancement features and cell proliferative activity determined by DNA S-phase percentage. Cancer. 1996, 77: 1844-1849. 10.1002/(SICI)1097-0142(19960501)77:9<1844::AID-CNCR13>3.0.CO;2-#.CrossRefPubMed
30.
go back to reference Adams TE, Alpert S, Hanahan D: Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature. 1987, 325: 223-228. 10.1038/325223a0.CrossRefPubMed Adams TE, Alpert S, Hanahan D: Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature. 1987, 325: 223-228. 10.1038/325223a0.CrossRefPubMed
31.
go back to reference Gonzalez LO, Pidal I, Junquera S, Corte MD, Vazquez J, Rodriguez JC, Lamelas ML, Merino AM, Garcia-Muniz JL, Vizoso FJ: Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer. 2007, 97: 957-963. 10.1038/sj.bjc.6603935.CrossRefPubMedPubMedCentral Gonzalez LO, Pidal I, Junquera S, Corte MD, Vazquez J, Rodriguez JC, Lamelas ML, Merino AM, Garcia-Muniz JL, Vizoso FJ: Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer. 2007, 97: 957-963. 10.1038/sj.bjc.6603935.CrossRefPubMedPubMedCentral
Metadata
Title
Relationship between morphological features and kinetic patterns of enhancement of the dynamic breast magnetic resonance imaging and clinico-pathological and biological factors in invasive breast cancer
Authors
Oscar Fernández-Guinea
Alejandro Andicoechea
Luis O González
Salomé González-Reyes
Antonio M Merino
Luis C Hernández
Alfonso López-Muñiz
Paz García-Pravia
Francisco J Vizoso
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-8

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine